antifungal agent6

Antifungal agent 6 shows antifungal activity.

Antifungal agent 76 has broad-spectrum antifungal activity with a MIC value of 0.25-16 μg mL.Antifungal agent 76 may act by disrupting fungal cell membranes and can be used to study fungal infections.

Antifungal Agent 61 (Compound 38) is an antifungal agent that inhibits V. mali, with an EC50 value of 0.50 mg/L. This compound impedes V. mali's growth by inducing cell deformation and contraction, diminishing intracellular mitochondrial count, thickening the cell wall, and enhancing cell membrane permeability [1].

Antiproliferative agent-6 (compound 8a) is a potent antitumor compound exhibiting antiproliferative activity. It inhibits cancer cell lines HCT116, MCF-7, H460, and non-tumor aneuploid immortal keratinocyte HaCaT cells with GI50 values of 0.5 μM, 2 μM, 0.7 μM, and 3.5 μM, respectively.

Antifungal agent 25 is an effective, broad-spectrum, metabolically stable antifungal agent in vivo. antifungal agent 25 exhibits antifungal effects against both Candida albicans and fluconazole-resistant Candida albicans.

Antifungal agent 33 (compound 4e) exhibits potent antifungal activity against Candida albicans with a minimum inhibitory concentration (MIC) of 16 μg ml and an IC50 of 0.19 μg ml.

Pradimicin A derivative 26 exhibits antifungal, antiviral, and antiparasitic properties by attaching to d-mannose (Man)-rich glycans in pathogenic organisms [1].

Antifungal Agent 29 (compound 9d) is a potent, selective, and non-toxic agent effective against Cryptococcus neoformans, exhibiting an MIC of ≤0.23 μM [1].

Antifungal agent 51 (5c) exhibits potent antifungal activity against Candida albicans FDC 151, Candida parapsilosis ATCC 22019, and Candida tropicalis FDC 138, with a minimum inhibitory concentration (MIC) value of less than 0.063 μg/mL. It demonstrates low toxicity to cells and no carcinogenicity [1].

Antifungal agent 28 (compound 18) is a selective and potent antifungal agent that disrupts mature Candida biofilms and inhibits pathogenic strains of Candida albicans and non-Candida albicans, including fluconazole-resistant strains.

GABAA receptor agent 6 (compound 2027) is a potent γ-GABAAR antagonist with low cellular membrane permeability (Ki = 0.56 μM) [1].

Antifungal agent 50 exhibits minimum inhibitory concentrations (MICs) ranging from less than 0.063 to 1 μg/mL [1].

Antifungal agent 73 (compound A32) effectively combats azole-resistant candidiasis by disrupting the fungal cell wall and membrane, demonstrating potent in vivo activity against pathogenic fungi, including fluconazole-resistant strains [1].

Compound 9 (Antifungal agent 67), an imidazole class antifungal, exhibits efficacy against Candida and possesses a CC50 value of 33.6 μM in neonatal rat cardiomyoblasts [1].

Antifungal agent 68 (compound 10) effectively combats fungal infections caused by Candida and Cryptococcus gattii through the inhibition of ergosterol biosynthesis, likely via interaction with lanosterol 14α-demethylase (CYP51). The imidazole ring of antifungal agent 68 is proposed to interact with the heme group of CYP51 [1].

Antifungal agent 19 demonstrates potent antifungal activity (EC50 = 0.72 μM).

Compound 24f, an antifungal agent also known as 'Antifungal agent 85,' demonstrates potent antibacterial properties, exhibiting minimum inhibitory concentration (MIC) values ranging from 2.5 to 10 μM against diverse Gram-positive bacteria [1].

Antifungal agent 24 (Compound 6) is an antifungal agent that inhibits Candida albicans [MIC: 0.03 μg ml].

Antifungal agent 17 showed good antifungal activity against B. cinerea (EC50: 2.86 μg/mL).

Antiparasitic agent-6 (compound 5b) demonstrates selective antiparasitic activity against Leishmania infantum (L. infantum) with an IC50 of 3.89 μM and exhibits cytotoxicity against HepG2 cells with a CC50 of 13.64 μM [1].

Antifungal agent 100 (compound 3i) demonstrates notable antifungal activity, exhibiting an EC 50 of 0.33 mg L against S. sclerotiorum. It also possesses an IC 50 value of 0.63 mg mL targeting the Succinate dehydrogenase (SDH) of the same organism [1].

Antifungal agent 54 (compound A05) is a potent inhibitor against Fluconazole-resistant strains, outperforming Miconazole in efficacy. It exhibits significant activity against Candida albicans, with minimum inhibitory concentration (MIC) values ranging from 0.25-1 μg mL [1].

Antifungalagent 108 (compound 14d) is an original imidazo[1,2-b]pyridazine derivative that exhibits potent antifungal activity against Madurella mycetomatis (MM55 strain) with an IC50 of 0.9 μM. The compound shows an IC50 of 14.3 μM for cell viability in NIH-3T3 mouse fibroblasts.

Compound Im (Insecticidal agent 6) is a potent inhibitor of insect ryanodine receptors (RyRs), exhibiting an EC50 of 0.6308 µM against S. frugiperda RyRs. It demonstrates outstanding insecticidal efficacy against lepidopteran pests and has applications in pest and disease research [1].

Compound 5c (Antifungal agent 64) exhibits potent fungicidal activity against Fusarium oxysporum f.sp. cucumerinum and is applicable for research in antiviral and fungicidal domains [1].

Antifungal agent 52 (compound 6c), a tetrazole derivative, inhibits ergosterol synthesis and significantly exhibits antifungal activity against Candida albicans by affecting the permeabilization of the C. albicans sessile cell membrane [1].

Antifungal agent 14 demonstrates potent broad-spectrum antifungal activity, effectively targeting a variety of fungal strains with exceptional minimum inhibitory concentration values.

Antifungal agent 38 is a heterocyclic disulfide with antifungal and antibacterial properties. It induces hyphal shrinkage, disrupts plasma membrane integrity, and causes cell content damage and leakage [1].

Compound 2f (Antifungal Agent 46) is a potent antifungal that inhibits Ras signaling by targeting protein farnesyltransferase [1].

Antitrypanosomal agent 6 (compound 18a) is a potent antitrypanosomal agent demonstrating good ADME properties, with an IC50 of 0.47 μM against Trypanosoma brucei (T. brucei), making it more than twice as active as Nifurtimox; it also exhibits a strong interaction with and selective binding to AT-rich DNA.

Antifungal agent 49 (Example 112) demonstrates activity against Cryptococcus neoformans with a minimum inhibitory concentration (MIC) of 49 μM [1].

Antifungal Agent 70 (Compound 13), a dihydroeugenol-imidazole, exhibits efficacy against multi-resistant Candida auris with a minimum inhibitory concentration (MIC) of 36.4 μM, demonstrating notable antifungal activity [1].

Compound 5d (Antifungal Agent 65) exhibits potent fungicidal activity against Fusarium oxysporum f.sp. cucumerinum and is utilized in antiviral and fungicidal research [1].

Antifungal agent 74 (compound 3c), is a potent substance that exhibits excellent fungicidal activity against C. arachidicola and R. solani, functioning by disrupting steroid biosynthesis and ribosome biogenesis in eukaryotes [1].

Compound 3i (Antifungal agent 63) is a fungicidal agent displaying potent activity against Fusarium oxysporum f.sp. cucumerinum and has applications in antiviral and fungicidal research [1].

Antifungal agent 90 (Compound 7n), known for inhibiting ergosterol biosynthesis, demonstrates potent antifungal activity. It exhibits effective control against Valsa mali and Botrytis cinerea, with EC 50 values of 4.26 and 1.41 μg mL, respectively [1].

Antifungal agent 87(10) is a highly potent PDT antimycotic photosensitizer (PDT-IC₅₀ = 1 nM for T. rubrum) [1].

Antifungalagent 105 (compound A25) is an effective antifungal agent that offers both protective and therapeutic benefits.

Antifungal agent 77 (Compound 13h) exhibits both antifungal properties and effective insecticidal activity against Mythimna separata, Helicoverpa armigera, Ostrinia nubilalis, and Spodoptera frugiperda, with mortality rates of 30%, 25%, 40%, and 25% respectively at a concentration of 500 μg mL. Additionally, it demonstrates toxicity in zebrafish embryos with an LC50 of 2.43 μg mL [1].

Antifungal agent 18 is a new antifungal compound used for treating fungal infections.

Antifungal agent 1 is an effective antifungal agent.

Anti-MRSA agent 6 (compound 3q6) is a potent anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agent with low cytotoxicity for MCF-7 and A549 cells [1].

Antifungal agent 16 has antimicrobial activity comparable to that of ciprofloxacin and has higher antifungal activity than fluconazole.

Antifungal agent 11 has a good antifungal effect.

Antifungal agent 56 (compound A09) is a potent antifungal, demonstrating superior efficacy against Fluconazole-resistant strains and outperforming Miconazole, effectively inhibiting Candida albicans strains with minimal inhibitory concentration (MIC) values ranging from 0.03 to 0.25 μg mL [1].

Antifungal Agent 53 (A03), a potent Candida albicans CYP51 inhibitor, exhibits antifungal activity by preventing fungi biofilm formation and demonstrates good safety [1].

Antifungal agent 55 (Compound A07) effectively inhibits Fluconazole-resistant strains of Candida albicans, demonstrating greater efficacy than Miconazole. It exhibits minimum inhibitory concentrations (MIC) values ranging from 0.25-1 μg/mL [1].

Antifungal agent 30 is a potent antifungal agent that exhibits good antifungal activity against Candida albicans (CPCC400616) (MIC: 0.03 μg/mL) and Aspergillus fumigatus (MIC: 0.5 μg/mL). Antifungal agent 30 exerts antifungal activity through hydrogen and ligand interactions with CYP51.